New Evidence Published Supporting Use of DecisionDx®-SCC Test in Guiding and Improving Treatment Pathway Decisions in NCCN High-Risk Cutaneous Squamous Cell Carcinoma
CSTLCastle announced the publication of two new studies related to its DecisionDx-SCC test for patients with high-risk cutaneous squamous cell carcinoma.
Castle Biosciences to Participate in Upcoming Investor Conferences
CSTLCastle Biosciences will participate in three investor conferences in September
Castellum, Inc. Reports Record Quarterly Revenue, Improving Profitability, and Additional Debt Reduction with Q2 2025 Results
CSTLCastellum, Inc. Reports Record Quarterly Revenue, Improving Profitability and Additional Debt Reduction with Q2 2025 Results
Castle Biosciences Enters Collaboration and License Agreement with SciBase to Develop Diagnostic Tests for Dermatologic Diseases
CSTLCastle Biosciences, Inc. today announced that it has entered entered into a collaboration and license agreement with SciBase Holding AB.
Castle Biosciences Announces It Will Present Research Aimed At Enhancing The Clinical Management Of Patients With Cutaneous Melanoma And Uveal Melanoma At The 2025 American Society Of Clinical Oncology Annual Meeting
CSTLScotiabank Maintains Sector Outperform on Castle Biosciences, Lowers Price Target to $40
CSTLCastle Biosciences Unveils Real-World Data Supporting PRAME Integration to Enhance Uveal Melanoma Risk Prediction
CSTLLake Street Maintains Buy on Castle Biosciences, Lowers Price Target to $35
CSTLNike To $70? Here Are 10 Top Analyst Forecasts For Tuesday
CSTLIchor Holdings Posts Weak Earnings, Joins Fabrinet, Vertex Pharmaceuticals And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
CSTLCanaccord Genuity Maintains Buy on Castle Biosciences, Lowers Price Target to $37
CSTLCastle Biosciences Signs Definitive Agreement To Acquire Capsulomics; Terms Not Disclosed
CSTLCastle Biosciences Raises FY2025 Sales Guidance from $280.00M-$295.00M to $287.00M-$297.00M vs $289.17M Est
CSTLCastle Biosciences Q1 EPS $(0.20) Misses $(0.07) Estimate, Sales $88.00M Beat $80.38M Estimate
CSTLCastle Biosciences To Share New Data at DDW 2025 Highlighting TissueCypher Test's Ability To Identify Patients At Increased Risk For Developing Esophageal Cancer
CSTLCastle Biosciences' New Study In Cancer Diagnosis & Prognosis Demonstrates That DecisionDx-melanoma Outperforms Both AJCC Staging And CP-GEP Test
CSTLCastle Biosciences Surpasses 200,000 DecisionDx-Melanoma Clinical Test Orders
CSTLCastle Biosciences To Share New Research Data at AACR Annual Meeting Highlighting Use Of DecisionDx-Melanoma To Identify Early-Stage Melanoma Patients At High Risk of Distant Metastasis
CSTLCastle Biosciences Announced The Recent Publication Of Two Papers In The World Journal Of Surgical Oncology And Cancer Medicine Sharing Reports From The Prospective, Multicenter Decide Study Demonstrating The Significant Impact Of The Company's DecisionDx
CSTLCastle Biosciences Announces It Will Present New Data At EADO April 3-5, 2025 In Athens, Greece Supporting The Clinical Value of the DecisionDx Melanoma Test in Guiding Risk-Aligned Management Of Patients With Melanoma
CSTLBaird Maintains Outperform on Castle Biosciences, Raises Price Target to $37
CSTLCastle Biosciences Narrows FY2025 Sales Guidance from $255.00M-$330.00M to $280.00M-$295.00M vs $274.09M Est
CSTLCastle Biosciences Q4 2024 GAAP EPS $0.32 Up From $(0.10) YoY, Sales $86.311M Beat $81.911M Estimate
CSTLCastle Biosciences To Share Data Reinforcing The Clinical Value Of Its Dermatologic Portfolio Of Gene Expression Profile Tests At The 22nd Annual Winter Clinical Dermatology Conference Feb. 14-19
CSTLCastle Biosciences Reports Preliminary 2024 Results: Expects $320M-$330M In Annual Revenue (+50% YoY), 96,071 Total Tests Delivered (+36% YoY), And $293M In Cash And Investments
CSTLCastle Biosciences Advances Test to Predict Super Response in Atopic Dermatitis
CSTLScotiabank Maintains Sector Outperform on Castle Biosciences, Raises Price Target to $44
CSTLCastle Biosciences Announced The Latest Data From Its Prospective, Multicenter Decide Study Exploring The Impact Of Integrating DecisionDx-melanoma Test Results Into SLNB Decision-making For Patients Recently Diagnosed With Melanoma
CSTLLake Street Maintains Buy on Castle Biosciences, Raises Price Target to $40
CSTLKeybanc Maintains Overweight on Castle Biosciences, Raises Price Target to $36
CSTLBaird Maintains Outperform on Castle Biosciences, Raises Price Target to $39
CSTLCastle Biosciences Sees FY24 Revenue From $275M-$300M To $320M-$330M Vs $297.988M Est.
CSTLCastle Biosciences Q3 2024 GAAP EPS $0.08 Beats $(0.03) Estimate, Sales $85.800M Beat $79.842M Estimate
CSTLCathie Wood's ARK Invest Fund Sales From Monday, May 2, 2022: TRMB, SPLK, TSLA, CSTL, LHX
CSTLCastle Biosciences Announces Expanded U.S. Federal Supply Schedule Contract Covering Its Entire Dermatologic Cancer Portfolio Of Tests
CSTL